-

Nimble Therapeutics Appoints Cyrus Arman, PhD, MBA as Chief Business Officer

MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, an industry-leading peptide therapeutic discovery and optimization company, today announced the appointment of Dr. Cyrus Arman as Chief Business Officer. Cyrus will be responsible for structuring strategic alliances, licensing agreements, and financial investments, and will further provide management and strategic leadership to the organization. The appointment comes at a time of significant growth for Nimble Therapeutics, as the company continues to advance its technology platform and build out its strategic partnerships. His appointment represents the first step in Nimble’s expansion toward becoming a fully integrated biotechnology company.

Cyrus has over 12 years of experience in corporate, clinical, and commercial strategy. Most recently, he served as Vice President of Corporate Development and Strategy at NEUVOGEN, Inc, an immuno-oncology firm developing cancer vaccines. Prior to NEUVOGEN, Dr. Arman contributed to rebuilding and running Amgen’s Global Competitive Intelligence and Strategy unit, and later served as a Director in Amgen’s Corporate Strategy group.

“We’re excited to welcome Cyrus to our management team at Nimble,” said Jigar Patel, PhD, Founder and CEO of Nimble Therapeutics. “Cyrus brings valuable experience devising strategy, executing transactions, and leveraging innovation that will enable Nimble to deliver on the promise of peptide therapeutics.”

Cyrus has an MBA from the University of California Los Angeles, a PhD in Neuroscience and an MS in Biomedical Engineering from the University of Southern California, and a BS in Biopsychology from the University of California San Diego.

About Nimble Therapeutics

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful analytics to efficiently and intelligently discover and develop next generation peptide therapeutics.

Connect with us on LinkedIn at www.linkedin.com/company/nimble-therapeutics or visit our website at www.nimbletherapeutics.com to learn more.

Contacts

Nimble Therapeutics, Inc.
Brad Garcia, PhD
Vice President, Corporate Development
info@nimbletherapeutics.com

NIMBLE THERAPEUTICS, INC.

Details
Headquarters: Madison, Wisconsin
CEO: Jigar Patel
Employees: 39
Organization: PRI

Release Versions

Contacts

Nimble Therapeutics, Inc.
Brad Garcia, PhD
Vice President, Corporate Development
info@nimbletherapeutics.com

Social Media Profiles
More News From NIMBLE THERAPEUTICS, INC.

Nimble Announces Formation of a World-Class Scientific Advisory Board

MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, Inc. Announces Formation of a World-Class Scientific Advisory Board....

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

PHILADELPHIA--(BUSINESS WIRE)--Nimble Therapeutics today announced the opening of a second R&D site in Philadelphia, PA. The new site, located in B+Labs, a hub for scientific innovation in University City Philadelphia, will focus on progressing Nimble’s growing pipeline of orally-delivered peptide therapeutics into clinical development. The Philadelphia site will synergize with activities at Nimble’s main R&D site in Madison, WI, which is focused on leveraging its proprietary platform t...

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors. Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline. Dr. Flynn has over 40 years of experience in the discovery and development of high-impact medicines. He recently retired from Deciphera Pharmaceuticals, a company he founded in 2003. At Deciphera, Dr. Flynn held positions...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.